Analysis of the Determinants of Adherence to Coadministration of Flu Vaccination With the Booster of COVID-19 Vaccine

NCT ID: NCT05781191

Last Updated: 2024-03-18

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 8231 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2021-11-13
• Study Completion Date: 2021-12-31

Brief Summary

This study investigates healthcare workers' attitudes towards co-administering COVID-19 and seasonal influenza vaccines, a method supported globally for its efficiency and potential to lessen healthcare burdens. It explores various factors affecting workers' willingness to accept or decline this approach, ranging from demographic to logistical aspects, and examines the link between vaccine hesitancy and co-administration acceptance, aiming to identify and address hesitancy towards both vaccines

Detailed Description

Analysis of the determinants of refusal and adherence to the coadministration of influenza vaccination with the booster dose of anti-SARS-CoV-2 vaccine conducted on healthcare personnel of the University Polyclinic Foundation "A. Gemelli" IRCCS New evidence now suggests that co-administration of COVID-19 vaccines with inactivated vaccines is acceptable in terms of immunogenicity and reactogenicity. In particular, a recent randomized placebo-controlled phase IV study, established that both ChAdOx1 and BNT162b2 COVID-19 vaccines could be safely co-administered with seasonal influenza (SIV) vaccines adjuvanted with MF59 or derived from cell culture, without any clinically significant increase in adverse events or immunologic inference.

Although limited data are available, Interim Guidelines issued by WHO suggest that such co-administration is acceptable. The U.S. Centers for Disease Control and Prevention (CDC) supports that COVID-19 vaccines can be co-administered with other vaccines, including SIV. Similarly, in October 2021 (i.e., just before the start of the 2021/2022 flu vaccination campaign), the Italian Ministry of Health gave the go-ahead for co-administration of the vaccine.

Vaccination programs against COVID-19 and seasonal influenza are currently being implemented in parallel in many countries. The administration of both vaccines during the same session would have several advantages. At the individual level, it would reduce the number of necessary health visits and provide timely protection against both diseases; these individual benefits may encourage greater uptake of the two vaccines. Also from the perspective of health system organization and management, co-administration could facilitate the implementation of both vaccine programs and reduce the overall burden on health services.

The primary objective of the study is to measure the modifiable and non-modifiable, subjective and objective, demographic, economic, social, cultural, occupational, logistical and personal determinants of refusal or adherence to co-administration of seasonal influenza vaccination with the booster dose of anti-SARS-CoV vaccine-Evaluate the association between refusal of co-administration and vaccine hesitancy, both general and specific for influenza and/or SARS-cov-2;

1. Identify subgroups most at risk of refusing co-administration;

2. Identify the most appropriate interventions and/or incentives to overcome the main determinants of refusal to co-administer;

3. Identify the most appropriate interventions and/or incentives to overcome the main determinants of co-administration refusal.

Conditions

Influenza; COVID-19

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: OTHER

Study Groups

Employees

COMIRNATY

Intervention Type: BIOLOGICAL

Booster (3rd) dose of COMIRNATY Seasonal dose of influenza vaccination based on patient's individual risk factors

Interventions

COMIRNATY

Booster (3rd) dose of COMIRNATY Seasonal dose of influenza vaccination based on patient's individual risk factors

Intervention Type: BIOLOGICAL

Other Intervention Names

FLUAD TETRA; FLUCELVAX TETRA; FLUARIX TETRA

Eligibility Criteria

Inclusion Criteria

• All healthcare workers and non-employees of FPG and all Physicians in Specialty Training attached to UCSC will be enrolled during the period when the possibility of coadministration of the two vaccines (Sars-CoV-2 and influenza) was available at the Foundation at the Covid-19 Vaccine Center set up at Presidio Columbus and/or at specially designated facilities, i.e., between November 13, 2021 and December 31, 2021.

Exclusion Criteria

• All individuals who have received vaccinations, influenza and/or anti-SARS-CoV-2 with booster dose, outside the window in which coadministration was available at FPG will be excluded.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

Sponsor Role: lead

Responsible Party

Laurenti Patrizia

Chief of the Complex Operative Unit of Hospital Hygiene, University Polyclinic Foundation "A. Gemelli" IRCCS, Rome

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Patrizia Laurenti, MD

Role: PRINCIPAL_INVESTIGATOR

Fondazione Policlinico Universitario A. Gemelli IRCCS - Rome

Locations

Fondazione Policlinico Gemelli

Roma, RM, Italy

Countries

Italy

Other Identifiers

5169

Identifier Type: -

Identifier Source: org_study_id